Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Urothelial04 adjuvant datopotamab deruxtecan + rilvegostomig in high-risk muscle-invasive urothelial carcinoma
2025-525030-57-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Oct 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 16
01
Overview
Phase 3, randomised, open-label trial in transitional cell carcinoma (TCC) comparing Datopotamab deruxtecan + rilvegostomig with Standard of care adjuvant therapy (2 arms). Primary endpoint: Disease-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
datopotamab deruxtecanrilvegostomig
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2025-525030-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525030-57-00.